Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.63 |
| ▸ | RAB9A | P51151 | 2/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | VDR | P11473 | 1/20 | 0.48 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.47 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.47 |
| ▸ | RORC | P51449 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL694844 | 0.88 | PKM (0.59) | MAPTRAB9AL3MBTL1TDP1LMNA | |
| SCHEMBL695301 | 0.82 | L3MBTL1 (0.54) | MAPTRAB9AL3MBTL1LMNASMN1; SMN2 | |
| SCHEMBL25686475 | 0.81 | MAPT (0.75) | MAPTRAB9AL3MBTL1TDP1LMNA | |
| SCHEMBL14274445 | 0.80 | MAPT (0.89) | MAPTRAB9AL3MBTL1TDP1LMNA | |
| SCHEMBL5284759 | 0.79 | MAPT (1.00) | MAPTRAB9AL3MBTL1TDP1LMNA | |
| SCHEMBL1951546 | 0.78 | MAPT (1.00) | MAPTRAB9AL3MBTL1TDP1LMNA | |
| SCHEMBL11605162 | 0.76 | MEN1 (0.58) | MAPTL3MBTL1TDP1LMNASMN1; SMN2 | |
| SCHEMBL26627769 | 0.76 | MAPT (0.80) | MAPTRAB9AL3MBTL1TDP1LMNA | |
| SCHEMBL21063817 | 0.76 | MAPT (0.80) | MAPTRAB9AL3MBTL1TDP1LMNA | |
| SCHEMBL16517520 | 0.76 | TSHR (0.57) | MAPTRAB9AL3MBTL1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115907-A1 | NOVEL COMPOUNDS AS INHIBITORS OF RENIN | CADILA HEALTHCARE LIMITED (IN) | 2012-05-10 | — | — | US | disclosed |
| EP-2421828-A2 | PIPERIDINE DERIVATIVES AS INHIBITORS OF RENIN | Cadila Healthcare Limited (IN) | 2012-02-29 | — | — | EP | disclosed |
| WO-2010122580-A2 | NOVEL COMPOUNDS AS INHIBITORS OF RENIN | CADILA HEALTHCARE LIMITED (IN) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115907-A1 | NOVEL COMPOUNDS AS INHIBITORS OF RENIN | REN, ACE, AGTR1 | MAPT 202/4885RAB9A 529/4885L3MBTL1 4879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.